Long-term survival analysis of a randomized phase II study of front-line chemo-immunotherapy with carboplatin-paclitaxel using oregovomab indirect immunization in advanced ovarian cancer (QPT-ORE-002).

Authors: Corrado Terranova, Vanda Salutari, Francesco Plotti, Francesco Raspagliesi, Caterina Ricci, Violante Di Donato, Paolo Scollo, Elena Giudice, Maria Grazia Distefano, Sunil Gupta, Jada Srinivasa Rao, Roberto Angioli, Giovanni Scambia

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.e17592

Source: Full article

---

Abstract

e17592